Analysts Set Expectations for Genmab A/S’s FY2025 Earnings (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB) – Equities research analysts at Leerink Partnrs cut their FY2025 EPS estimates for shares of Genmab A/S in a report released on Thursday, August 8th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of $1.53 per share for the year, down from their previous estimate of $1.56. The consensus estimate for Genmab A/S’s current full-year earnings is $1.13 per share.

GMAB has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Friday, August 9th. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Truist Financial lifted their price target on shares of Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. Finally, BTIG Research increased their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $49.50.

Genmab A/S Stock Up 0.2 %

GMAB stock opened at $26.57 on Monday. The business has a fifty day moving average of $26.71 and a two-hundred day moving average of $28.20. The stock has a market cap of $17.57 billion, a price-to-earnings ratio of 22.14, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97. Genmab A/S has a 52-week low of $24.53 and a 52-week high of $39.53.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. DDD Partners LLC acquired a new position in shares of Genmab A/S in the second quarter worth $8,860,000. Capital International Investors grew its stake in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares in the last quarter. First Trust Advisors LP increased its holdings in Genmab A/S by 16.0% during the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock worth $40,440,000 after purchasing an additional 175,292 shares during the period. Trexquant Investment LP purchased a new position in Genmab A/S in the fourth quarter worth approximately $4,875,000. Finally, Renaissance Technologies LLC grew its holdings in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.